The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.

Simple item page
dc.contributor.authorGhatnekar, Gautam S.en
dc.contributor.authorGrek, Christina L.en
dc.contributor.authorArmstrong, David G.en
dc.contributor.authorDesai, Sanjay C.en
dc.contributor.authorGourdie, Robert G.en
dc.contributor.departmentBiomedical Engineering and Mechanicsen
dc.contributor.departmentFralin Biomedical Research Instituteen
dc.coverage.spatialUnited Statesen
dc.date.accessioned2017-02-09T20:21:44Zen
dc.date.available2017-02-09T20:21:44Zen
dc.date.issued2015-01en
dc.description.abstractThe gap junction protein, connexin43 (Cx43), has critical roles in the inflammatory, edematous, and fibrotic processes following dermal injury and during wound healing, and is abnormally upregulated at the epidermal wound margins of venous leg ulcers (VLUs). Targeting Cx43 with ACT1, a peptide mimetic of the carboxyl-terminus of Cx43, accelerates fibroblast migration and proliferation, and wound reepithelialization. In a prospective, multicenter clinical trial conducted in India, adults with chronic VLUs were randomized to treatment with an ACT1 gel formulation plus conventional standard-of-care (SOC) protocols, involving maintaining wound moisture and four-layer compression bandage therapy, or SOC protocols alone. The primary end point was mean percent ulcer reepithelialization from baseline to 12 weeks. A significantly greater reduction in mean percent ulcer area from baseline to 12 weeks was associated with the incorporation of ACT1 therapy (79% (SD 50.4)) as compared with compression bandage therapy alone (36% (SD 179.8); P=0.02). Evaluation of secondary efficacy end points indicated a reduced median time to 50 and 100% ulcer reepithelialization for ACT1-treated ulcers. Incorporation of ACT1 in SOC protocols may represent a well-tolerated, highly effective therapeutic strategy that expedites chronic venous ulcer healing by treating the underlying ulcer pathophysiology through Cx43-mediated pathways.en
dc.description.versionPublished versionen
dc.format.extent289 - 298 page(s)en
dc.identifier.doihttps://doi.org/10.1038/jid.2014.318en
dc.identifier.eissn1523-1747en
dc.identifier.issue1en
dc.identifier.urihttp://hdl.handle.net/10919/74988en
dc.identifier.volume135en
dc.languageengen
dc.relation.urihttp://www.ncbi.nlm.nih.gov/pubmed/25072595en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectAdulten
dc.subjectChronic Diseaseen
dc.subjectConnexin 43en
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectKaplan-Meier Estimateen
dc.subjectLeg Ulceren
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPeptidesen
dc.subjectProspective Studiesen
dc.subjectProtein Structure, Tertiaryen
dc.subjectTreatment Outcomeen
dc.subjectWound Healingen
dc.titleThe effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.en
dc.title.serialJournal of Investigative Dermatologyen
dc.typeArticle - Refereeden
dc.type.otherMulticenter Studyen
dc.type.otherRandomized Controlled Trialen
dc.type.otherResearch Support, Non-U.S. Gov'ten
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/University Research Institutesen
pubs.organisational-group/Virginia Tech/University Research Institutes/Virginia Tech Carilion Research Instituteen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.pdf
Size:
331.42 KB
Format:
Adobe Portable Document Format
Description:
Publisher's Version
Download
License bundle
Now showing 1 - 1 of 1
Name:
VTUL_Distribution_License_2016_05_09.pdf
Size:
18.09 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

All Faculty Deposits
Scholarly Works, Biomedical Engineering and Mechanics
Scholarly Works, Fralin Biomedical Research Institute at VTC